Featured Research

from universities, journals, and other organizations

Hepatitis E Takes A Piggyback

Date:
May 14, 2007
Source:
BioMed Central
Summary:
Pigs carry hepatitis E virus (HEV), which they can pass on to humans. Scientists analysed blood test data from 2,500 pigs, natural hosts for the virus, on Japanese farms. They found that by the age of 150 days, over 95% of pigs had been infected with HEV.

Pigs carry hepatitis E virus (HEV), which they can pass on to humans. But now research from Japan published in Online Open Access journal BMC Veterinary Research says that pigs get HEV early enough to minimise the risk of human infection. The scenario humans need to worry about would occur if the infection rate in pigs drops. At low infection rates, there is actually a higher chance pigs will pass on HEV to humans at slaughter.

Kunio Satou and Hiroshi Nishiura analysed blood test data from 2,500 pigs, natural hosts for the virus, on Japanese farms at Hokkaido, Honshu and Kyushu. They found that by the age of 150 days, over 95% of pigs had been infected with HEV.

Inoculation studies have shown that the virus remains in pigs' faeces and some organs for up to 30 days after infection. This means that the chances of pigs excreting the virus when they are slaughtered at the age of 180 days are currently small. However, if the infection weakens and pigs don't get infected with HEV until they are older, more pigs will still be carrying the virus when they reach the slaughterhouse.

HEV, which is found worldwide, can potentially cause acute hepatitis in humans. So monitoring infection rates could help protect meat processors and vets. The disease can be transmitted by drinking water contaminated with faeces as well as by eating pork: uncooked wild boar liver is one Japanese delicacy that frequently leads to infection.

Suckling pigs don't contract the virus in their first 30 days, because a maternal antibody protects them. Vaccines are currently under development against HEV, although Satou and Nishiura suggest that changes in husbandry practices and avoiding eating raw liver might be more cost-effective measures should HEV's hold on pig farms weaken.

Article: Transmission dynamics of hepatitis E among swine: Potential impact upon human infection, Kunio Satou and Hiroshi Nishiura, BMC Veterinary Research


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Cite This Page:

BioMed Central. "Hepatitis E Takes A Piggyback." ScienceDaily. ScienceDaily, 14 May 2007. <www.sciencedaily.com/releases/2007/05/070510194116.htm>.
BioMed Central. (2007, May 14). Hepatitis E Takes A Piggyback. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/05/070510194116.htm
BioMed Central. "Hepatitis E Takes A Piggyback." ScienceDaily. www.sciencedaily.com/releases/2007/05/070510194116.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins